EMA starts second rolling review of a COVID-19 vaccine

The CHMP’s decision to start the rolling review of BNT162b2 (developed by BioNTech in collaboration with Pfizer) is based on preliminary results from non-clinical and early clinical studies in adults. Large-scale clinical trials involving several thousands of people are ongoing.

Source:

European Medicines Agency